Skip to main content
Top
Published in: Rheumatology International 6/2010

01-04-2010 | Short Communication

Elevation of serum IgG subclass concentration in patients with rheumatoid arthritis

Authors: Guigao Lin, Jinming Li

Published in: Rheumatology International | Issue 6/2010

Login to get access

Abstract

A new concept of IgG subclass such as IgG4-related systemic disease including autoimmune pancreatitis, characterized by a high-serum IgG4 level, has been proposed. Our aim was to investigate serum IgG subclass levels in rheumatoid arthritis (RA). IgG subclass levels of sera from 72 patients with rheumatoid arthritis were determined by immunonephelometric assay. The patients were divided into two groups according to clinical activity of the disease: active disease and remission. The sera from 45 normal controls were also measured. All statistical analyses were carried out with SPSS software version 13.0. We found a significant increase of all the four IgG subclass concentrations in sera of patients with RA compared to those of the controls (P < 0.001). When the patients were divided according to clinical activity, the IgG subclass concentrations were similar between the two groups (P > 0.05). Our data suggest that besides IgG1, IgG2 and IgG3, IgG4 may involve in the pathogenesis of the disease.
Literature
1.
go back to reference Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344:732–738CrossRefPubMed Hamano H, Kawa S, Horiuchi A, Unno H, Furuya N, Akamatsu T, Fukushima M, Nikaido T, Nakayama K, Usuda N, Kiyosawa K (2001) High serum IgG4 concentrations in patients with sclerosing pancreatitis. N Engl J Med 344:732–738CrossRefPubMed
2.
go back to reference Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G (2005) IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 139:542–550CrossRefPubMed Chapuy-Regaud S, Nogueira L, Clavel C, Sebbag M, Vincent C, Serre G (2005) IgG subclass distribution of the rheumatoid arthritis-specific autoantibodies to citrullinated fibrin. Clin Exp Immunol 139:542–550CrossRefPubMed
3.
go back to reference Martini A, Plebani A, Ravelli A, Avanzini MA, Jefferis R, Zonta L, Notarangelo LD, Ugazio AG, Burgio R (1986) IgG subclass serum levels in juvenile chronic arthritis. Ann Rheum Dis 45:400–404CrossRefPubMed Martini A, Plebani A, Ravelli A, Avanzini MA, Jefferis R, Zonta L, Notarangelo LD, Ugazio AG, Burgio R (1986) IgG subclass serum levels in juvenile chronic arthritis. Ann Rheum Dis 45:400–404CrossRefPubMed
4.
go back to reference Shakib F, Stanworth DR (1976) IgG subclass composition of rheumatoid arthritic sera and joint fluids. Ann Rheum Dis 35:263–266CrossRefPubMed Shakib F, Stanworth DR (1976) IgG subclass composition of rheumatoid arthritic sera and joint fluids. Ann Rheum Dis 35:263–266CrossRefPubMed
5.
go back to reference Pressac M, Allouche F, Circaud R, Aymard P (1995) Evaluation of human IgG subclass assays on Beckman array. Ann Clin Biochem 32(Pt 3):281–288PubMed Pressac M, Allouche F, Circaud R, Aymard P (1995) Evaluation of human IgG subclass assays on Beckman array. Ann Clin Biochem 32(Pt 3):281–288PubMed
6.
go back to reference Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRefPubMed
7.
go back to reference Fransen J, Langenegger T, Michel BA, Stucki G (2000) Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 39:321–327CrossRef Fransen J, Langenegger T, Michel BA, Stucki G (2000) Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. Rheumatology (Oxford) 39:321–327CrossRef
8.
go back to reference Martini A, Avanzini MA, Ravelli A, Zonta L, Plebani A, de Benedetti F, Burgio RG (1989) Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. Ann Rheum Dis 48:582–585CrossRefPubMed Martini A, Avanzini MA, Ravelli A, Zonta L, Plebani A, de Benedetti F, Burgio RG (1989) Variation of serum IgG subclass concentrations with disease activity in juvenile chronic arthritis. Ann Rheum Dis 48:582–585CrossRefPubMed
10.
go back to reference Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G, Mueller-Hilke B (2008) IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology (Oxford) 47:1489–1492CrossRef Engelmann R, Brandt J, Eggert M, Karberg K, Krause A, Neeck G, Mueller-Hilke B (2008) IgG1 and IgG4 are the predominant subclasses among auto-antibodies against two citrullinated antigens in RA. Rheumatology (Oxford) 47:1489–1492CrossRef
11.
go back to reference Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA (1987) The subclass distribution of human IgG rheumatoid factor. J Immunol 139:1466–1471PubMed Cohen PL, Cheek RL, Hadler JA, Yount WJ, Eisenberg RA (1987) The subclass distribution of human IgG rheumatoid factor. J Immunol 139:1466–1471PubMed
12.
go back to reference Mihai S, Chiriac MT, Herrero-Gonzalez JE, Goodall M, Jefferis R, Savage CO, Zillikens D, Sitaru C (2007) IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med 11:1117–1128CrossRefPubMed Mihai S, Chiriac MT, Herrero-Gonzalez JE, Goodall M, Jefferis R, Savage CO, Zillikens D, Sitaru C (2007) IgG4 autoantibodies induce dermal-epidermal separation. J Cell Mol Med 11:1117–1128CrossRefPubMed
13.
go back to reference Kawa S, Kitahara K, Hamano H, Ozaki Y, Arakura N, Yoshizawa K, Umemura T, Ota M, Mizoguchi S, Shimozuru Y, Bahram S (2008) A novel immunoglobulin - immunoglobulin interaction in autoimmunity. PLoS ONE 3:e1637CrossRefPubMed Kawa S, Kitahara K, Hamano H, Ozaki Y, Arakura N, Yoshizawa K, Umemura T, Ota M, Mizoguchi S, Shimozuru Y, Bahram S (2008) A novel immunoglobulin - immunoglobulin interaction in autoimmunity. PLoS ONE 3:e1637CrossRefPubMed
14.
go back to reference van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554–1557CrossRefPubMed van der Neut Kolfschoten M, Schuurman J, Losen M, Bleeker WK, Martínez-Martínez P, Vermeulen E, den Bleker TH, Wiegman L, Vink T, Aarden LA, De Baets MH, van de Winkel JG, Aalberse RC, Parren PW (2007) Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange. Science 317:1554–1557CrossRefPubMed
15.
go back to reference Aalberse RC, van der Gaag R, van Leeuwen J (1983) Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130:722–726PubMed Aalberse RC, van der Gaag R, van Leeuwen J (1983) Serologic aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4-restricted response. J Immunol 130:722–726PubMed
Metadata
Title
Elevation of serum IgG subclass concentration in patients with rheumatoid arthritis
Authors
Guigao Lin
Jinming Li
Publication date
01-04-2010
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 6/2010
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1330-8

Other articles of this Issue 6/2010

Rheumatology International 6/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine